|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||37.65 - 37.95|
|52-week range||34.30 - 69.00|
|Beta (3Y monthly)||0.55|
|PE ratio (TTM)||11.70|
|Forward dividend & yield||1.45 (3.82%)|
|1y target est||60.33|
How far off is Boiron SA (EPA:BOI) from its intrinsic value? Using the most recent financial data, we'll take a look...
France will end social security reimbursements for homeopathic drugs and the new policy - which has drawn the fire of alternative medicine advocates - will take full effect in 2021, the healthcare minister said on Tuesday. Healthcare Minister Agnes Buzyn told Le Parisien newspaper that there would be a phase-out period before 2021. France has long had a stronger attachment than many other countries to homeopathic drugs, which aim to treat patients with highly diluted substances, and is home to the world's biggest maker of the alternative medicine, Boiron.
Many investors define successful investing as beating the market average over the long term. But if you try your hand at stock picking, your risk returning less than the market. We regret to report that long term Boiron SA (E...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Does the February share price for BoironRead More...
Over the past 10 years Boiron SA (EPA:BOI) has been paying dividends to shareholders. The company is currently worth €861m, and now yields roughly 3.3%. Let's dig deeper into whether Read More...
Boiron SA (EPA:BOI) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In the case Read More...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
In this article, I’m going to take a look at Boiron SA’s (EPA:BOI) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...